Julia Sidenius Johansen

Medicine & Life Sciences

1. Biomarkers 100%
2. Colorectal Neoplasms 70%
3. Serum 65%
4. Rheumatoid Arthritis 57%
5. Adalimumab 43%
6. Survival 42%
7. Neoplasms 40%
8. C-Reactive Protein 38%
9. Cell-Free Nucleic Acids 35%
10. Methotrexate 35%
11. Interleukin-6 33%
12. Pancreatic Neoplasms 32%
13. MicroRNAs 31%
14. Inflammation 26%
15. Mortality 26%
16. Tumor Necrosis Factor Inhibitors 25%
17. Coronary Artery Disease 24%
18. Adenocarcinoma 23%
19. Bevacizumab 23%
20. Melanoma 21%
21. Population 21%
22. Therapeutics 21%
23. Joints 20%
24. Confidence Intervals 20%
25. Circulating Tumor DNA 20%
26. Antirheumatic Agents 20%
27. Placebos 19%
28. Oxaliplatin 19%
29. Chitinases 18%
30. Chitinase-3-Like Protein 1 18%
31. Healthy Volunteers 18%
32. Vascular Endothelial Growth Factor A 16%
33. Triamcinolone 16%
34. Bone Remodeling 16%
35. Myocardial Ischemia 16%
36. Cetuximab 15%
37. Tumor Necrosis Factor-alpha 15%
38. Mutation 15%